Caribou Q3 net loss $34.7M vs $10.0M YoY; cash $281M funds into H2 2026

Caribou Biosciences, Inc.

2024-Q3 EPS reported -$1.26 revenue$7,917,000

Revenue $2.0M, down from $23.7M due to AbbVie termination; R&D expense $30.4M.
Cash & equivalents $281M as of Sept 30, 2024, down from $372.4M at Dec 31, 2023.
CB-010 lupus GALLOP Phase 1 trial initiation expected by year-end 2024; Fast Track granted.
CB-011 CaMMouflage dose escalation data for r/r MM expected H1 2025; no DLTs observed.
Tina Albertson, MD/PhD, appointed CMO in August 2024; led BREYANZI development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.